Information Provided By: 
Fly News Breaks for October 25, 2016
BLUE
Oct 25, 2016 | 06:47 EDT
Piper Jaffray analyst Joshua Schimmer views the planned design for the pivotal trial of GBT-440 announced last night by bluebird bio for treatment of sickle cell disease as an indication that the FDA is willing to shift away from the traditional requirement of sickle crisis rates. This bodes well for bluebird finding its "own rapid path to market with a more reasonable dataset than many had been expecting," Schimmer tells investors in a research note. The analyst keeps an Overweight rating on the shares with a $95 price target.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
